209 related articles for article (PubMed ID: 37684337)
1. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy.
Ali A; Mekhaeil B; Biziotis OD; Tsakiridis EE; Ahmadi E; Wu J; Wang S; Singh K; Menjolian G; Farrell T; Mesci A; Liu S; Berg T; Bramson JL; Steinberg GR; Tsakiridis T
Commun Biol; 2023 Sep; 6(1):919. PubMed ID: 37684337
[TBL] [Abstract][Full Text] [Related]
2. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non-small cell lung cancer (NSCLC) through inhibition of HIF-1α.
Biziotis OD; Tsakiridis EE; Ali A; Ahmadi E; Wu J; Wang S; Mekhaeil B; Singh K; Menjolian G; Farrell T; Abdulkarim B; Sur RK; Mesci A; Ellis P; Berg T; Bramson JL; Muti P; Steinberg GR; Tsakiridis T
Mol Oncol; 2023 Nov; 17(11):2235-2256. PubMed ID: 37584455
[TBL] [Abstract][Full Text] [Related]
3. Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway.
Zhou J; Zhu J; Yu SJ; Ma HL; Chen J; Ding XF; Chen G; Liang Y; Zhang Q
Biomed Pharmacother; 2020 Dec; 132():110821. PubMed ID: 33068934
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin Inhibits Glioblastoma Growth and Proliferation by Activating AMPK.
Shoda K; Tsuji S; Nakamura S; Egashira Y; Enomoto Y; Nakayama N; Shimazawa M; Iwama T; Hara H
Cell Mol Neurobiol; 2023 Mar; 43(2):879-892. PubMed ID: 35435536
[TBL] [Abstract][Full Text] [Related]
5. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration.
Villani LA; Smith BK; Marcinko K; Ford RJ; Broadfield LA; Green AE; Houde VP; Muti P; Tsakiridis T; Steinberg GR
Mol Metab; 2016 Oct; 5(10):1048-1056. PubMed ID: 27689018
[TBL] [Abstract][Full Text] [Related]
6. Perturbations of cancer cell metabolism by the antidiabetic drug canagliflozin.
Papadopoli D; Uchenunu O; Palia R; Chekkal N; Hulea L; Topisirovic I; Pollak M; St-Pierre J
Neoplasia; 2021 Apr; 23(4):391-399. PubMed ID: 33784591
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms.
Mancini SJ; Boyd D; Katwan OJ; Strembitska A; Almabrouk TA; Kennedy S; Palmer TM; Salt IP
Sci Rep; 2018 Mar; 8(1):5276. PubMed ID: 29588466
[TBL] [Abstract][Full Text] [Related]
8. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
9. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
10. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice.
Day EA; Ford RJ; Lu JH; Lu R; Lundenberg L; Desjardins EM; Green AE; Lally JSV; Schertzer JD; Steinberg GR
Biochem J; 2020 Jun; 477(12):2347-2361. PubMed ID: 32510137
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
[TBL] [Abstract][Full Text] [Related]
12. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway.
Yang X; Liu Q; Li Y; Tang Q; Wu T; Chen L; Pu S; Zhao Y; Zhang G; Huang C; Zhang J; Zhang Z; Huang Y; Zou M; Shi X; Jiang W; Wang R; He J
Adipocyte; 2020 Dec; 9(1):484-494. PubMed ID: 32835596
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin mitigates carfilzomib-induced endothelial apoptosis via an AMPK-dependent pathway.
Dabour MS; Abdelgawad IY; Grant MKO; El-Sawaf ES; Zordoky BN
Biomed Pharmacother; 2023 Aug; 164():114907. PubMed ID: 37247463
[TBL] [Abstract][Full Text] [Related]
14. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
15. Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study.
Yuan Z; DeFalco FJ; Ryan PB; Schuemie MJ; Stang PE; Berlin JA; Desai M; Rosenthal N
Diabetes Obes Metab; 2018 Mar; 20(3):582-589. PubMed ID: 28898514
[TBL] [Abstract][Full Text] [Related]
16. Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [
van der Hoek S; Willemsen ATM; Visser T; Heeres A; Mulder DJ; Bokkers RPH; Slart RHJA; Elsinga PH; Heerspink HJL; Stevens J
Clin Pharmacol Ther; 2023 Jun; 113(6):1295-1303. PubMed ID: 36897753
[TBL] [Abstract][Full Text] [Related]
17. Model-Based Evaluation of Proximal Sodium Reabsorption Through SGLT2 in Health and Diabetes and the Effect of Inhibition With Canagliflozin.
Brady JA; Hallow KM
J Clin Pharmacol; 2018 Mar; 58(3):377-385. PubMed ID: 29144539
[TBL] [Abstract][Full Text] [Related]
18. Canagliflozin, an Inhibitor of the Na
Shim B; Stokum JA; Moyer M; Tsymbalyuk N; Tsymbalyuk O; Keledjian K; Ivanova S; Tosun C; Gerzanich V; Simard JM
Cells; 2023 Sep; 12(18):. PubMed ID: 37759444
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy.
Bardaweel S; Issa A
J Pharm Pharm Sci; 2022; 25():253-265. PubMed ID: 35977549
[TBL] [Abstract][Full Text] [Related]
20. Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin Antagonizes Salt-Sensitive Hypertension Through Modifying Transient Receptor Potential Channels 3 Mediated Vascular Calcium Handling.
Zhao Y; Li L; Lu Z; Hu Y; Zhang H; Sun F; Li Q; He C; Shu W; Wang L; Cao T; Luo Z; Yan Z; Liu D; Gao P; Zhu Z
J Am Heart Assoc; 2022 Aug; 11(15):e025328. PubMed ID: 35904193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
